Doctors Without Borders: AIDS Drug Discounts Threatened - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Doctors Without Borders: AIDS Drug Discounts Threatened



According to a price report by Medecins Sans Frontieres (MSF, or Doctors Without Borders) released July 18, 2011, several pharmaceutical companies have withdrawn drug price reductions in middle-income countries, such as India, Indonesia, Thailand, Vietnam, Ukraine, Colombia and Brazil.

“While there is continued progress to reduce prices for the poorest countries, a significant number of people with HIV/AIDS live in countries that are now excluded from price reductions,” said Nathan Ford, medical director of MSF’s Campaign for Access to Affordable Medicines, according to a press statement.

MSF started HIV treatments in Asia and Latin America over ten years ago, but handed responsibility over to local authorities on the assumption that people would gain access to treatment from government programmes. However, the drug company discount programmes do not apply to newer drugs. According to Janice Lee, HIV/AIDS pharmacist at MSF’s Campaign for Access to Essential Medicines, “When patents get in the way and drug companies refuse to cut prices, governments are going to have to start overriding patents so that they can afford to keep their HIV-positive people alive.”

The MSF price report also contains good news: once a day formulations containing tenofir have seen a 70% reduction in price due to generic competition allowing a move to a WHO-recommended, less toxic treatment.

Nevertheless, patents continue to be a barrier to reduced pricing across the board, and that could hinder the UN goal of providing universal access to antiretroviral therapy to all people living with HIV who are eligible for treatment.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here